Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trump Is Taking Hydroxychloroquine – But Global Prevention Trial Is Deadly Serious

Study Aims To Protect Healthcare Workers

Executive Summary

Experts fear Trump’s unregulated use of the malaria drug is dangerous, and muddies the waters around research which could still find chloroquine useful in preventing SARS-CoV-2 infection.

You may also be interested in...



Coronavirus Update: FDA Pulls Hydroxychloroquine Emergency Authorization, Germany Acquires Stake In CureVac

Plus news on the German government's decision to by a 23% stake in mRNA vaccines company CureVac, and Lilly taking Olumiant into Phase III.

Coronavirus Update: WHO Suspends Hydroxychloroquine Trial, Novavax Launches Phase I/II Vaccine Study

Mounting evidence that President Trump's 'game changer' does more harm than good for COVID-19 patients. Novovax and Medicago among the latest vaccine developers to report progress.

Coronavirus Notebook: US FDA Cuts Hotline Hours, Regulatory Relief May Be Permanent, Trump's Hydroxychloroquine Prescription

Dispatches from a world turned upside down include approval of more hydroxychloroquine ANDAs, a window into what post-pandemic regs at the US FDA might look like, and some bad news for night shift works who need coronavirus advice from the agency.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC142253

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel